Better Buy: Regeneron Pharmaceuticals, Inc. vs. Pfizer

Better Buy: Regeneron Pharmaceuticals, Inc. vs. Pfizer


Sales of Regeneron's lead product have been tapering off, but a handful of potential blockbusters could provide some big gains in 2017 and beyond. The pharma giant, meanwhile, also has some exciting growth drivers in its lineup, but an aging product line will make big gains difficult going forward.



from Biotech News